Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Efavirenz

×

Overview

What is Efavirenz?

Efavirenz is an HIV-1 specific, non-nucleoside, reverse transcriptase inhibitor (NNRTI). Efavirenz USP is chemically described as (S)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one. Its empirical formula is CHClFNO and its structural formula is:  

  Efavirenz USP is a white to slightly pink crystalline powder with a molecular mass of 315.68. It is practically insoluble in water (<10 microgram/mL). Efavirenz are available as film-coated tablets for oral administration containing 600 mg of efavirenz USP and the following inactive ingredients: microcrystalline cellulose, sodium lauryl sulfate, croscarmellose sodium, hydroxypropyl cellulose, lactose monohydrate, magnesium stearate. The film coating contains Opadry® Yellow (hypromellose, titanium dioxide, iron oxide yellow and polyethylene glycol).



What does Efavirenz look like?



What are the available doses of Efavirenz?

• Tablets: 600 mg

What should I talk to my health care provider before I take Efavirenz?

•Breastfeeding not recommended. •  Pregnancy testing and contraception are recommended. • Efavirenz tablets are not recommended for patients with moderate or severe hepatic impairment. Use caution in patients with mild hepatic impairment. • The incidence of rash was higher than in adults. (, ,

How should I use Efavirenz?

Efavirenz tablets in combination with other antiretroviral agents is  indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and in pediatric patients at least 3 months old and weighing at least 3.5 kg.

Monitor

[see Warnings and Precautions (

Efavirenz

[see Warnings and Precautions and Use in Specific Populationns (


What interacts with Efavirenz?

Sorry No Records found


What are the warnings of Efavirenz?

Sorry No Records found


What are the precautions of Efavirenz?

Sorry No Records found


What are the side effects of Efavirenz?

Sorry No records found


What should I look out for while using Efavirenz?

•tablets are contraindicated in patients with previously demonstrated clinically significant hypersensitivity (eg, Stevens-Johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of  components of this product. • of efavirenz with elbasvir and grazoprevir is contraindicated


What might happen if I take too much Efavirenz?

Some patients accidentally taking 600 mg twice daily have reported increased nervous system symptoms. One patient experienced involuntary muscle contractions. Treatment of overdose with efavirenz tablets should consist of general supportive measures, including monitoring of vital signs and observation of the patient’s clinical status. Administration of activated charcoal may be used to aid removal of unabsorbed drug. There is no specific antidote for overdose with efavirenz tablets. Since efavirenz is highly protein bound, dialysis is unlikely to significantly remove the drug from blood.


How should I store and handle Efavirenz?

Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] Protect from freezing.Clindamycin HCl capsules, USP (equivalent to 75 mg of clindamycin) are available as light green capsules imprinted with logo “LANNETT” on the cap and “1381” on the body and are supplied in: Bottles of 100 (NDC 0527-1381-01). Bottles of 200 (NDC 0527-1381-04). Clindamycin HCl capsules, USP (equivalent to 150 mg of clindamycin) are available as light blue opaque and light green capsules imprinted with logo “LANNETT” on the cap and “1382” on the body and are supplied in: Bottles of 100 (NDC 0527-1382-01). Clindamycin HCl capsules, USP (equivalent to 300 mg of clindamycin) are available as light blue opaque capsules imprinted with logo “LANNETT” on the cap and “1383” on the body and are supplied in: Bottles of 16 (NDC 0527-1383-02). Bottles of 100 (NDC 0527-1383-01). Dispense in a tight container with a child-resistant closure.Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].Clindamycin HCl capsules, USP (equivalent to 75 mg of clindamycin) are available as light green capsules imprinted with logo “LANNETT” on the cap and “1381” on the body and are supplied in: Bottles of 100 (NDC 0527-1381-01). Bottles of 200 (NDC 0527-1381-04). Clindamycin HCl capsules, USP (equivalent to 150 mg of clindamycin) are available as light blue opaque and light green capsules imprinted with logo “LANNETT” on the cap and “1382” on the body and are supplied in: Bottles of 100 (NDC 0527-1382-01). Clindamycin HCl capsules, USP (equivalent to 300 mg of clindamycin) are available as light blue opaque capsules imprinted with logo “LANNETT” on the cap and “1383” on the body and are supplied in: Bottles of 16 (NDC 0527-1383-02). Bottles of 100 (NDC 0527-1383-01). Dispense in a tight container with a child-resistant closure.Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].Clindamycin HCl capsules, USP (equivalent to 75 mg of clindamycin) are available as light green capsules imprinted with logo “LANNETT” on the cap and “1381” on the body and are supplied in: Bottles of 100 (NDC 0527-1381-01). Bottles of 200 (NDC 0527-1381-04). Clindamycin HCl capsules, USP (equivalent to 150 mg of clindamycin) are available as light blue opaque and light green capsules imprinted with logo “LANNETT” on the cap and “1382” on the body and are supplied in: Bottles of 100 (NDC 0527-1382-01). Clindamycin HCl capsules, USP (equivalent to 300 mg of clindamycin) are available as light blue opaque capsules imprinted with logo “LANNETT” on the cap and “1383” on the body and are supplied in: Bottles of 16 (NDC 0527-1383-02). Bottles of 100 (NDC 0527-1383-01). Dispense in a tight container with a child-resistant closure.Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].Clindamycin HCl capsules, USP (equivalent to 75 mg of clindamycin) are available as light green capsules imprinted with logo “LANNETT” on the cap and “1381” on the body and are supplied in: Bottles of 100 (NDC 0527-1381-01). Bottles of 200 (NDC 0527-1381-04). Clindamycin HCl capsules, USP (equivalent to 150 mg of clindamycin) are available as light blue opaque and light green capsules imprinted with logo “LANNETT” on the cap and “1382” on the body and are supplied in: Bottles of 100 (NDC 0527-1382-01). Clindamycin HCl capsules, USP (equivalent to 300 mg of clindamycin) are available as light blue opaque capsules imprinted with logo “LANNETT” on the cap and “1383” on the body and are supplied in: Bottles of 16 (NDC 0527-1383-02). Bottles of 100 (NDC 0527-1383-01). Dispense in a tight container with a child-resistant closure.Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].Clindamycin HCl capsules, USP (equivalent to 75 mg of clindamycin) are available as light green capsules imprinted with logo “LANNETT” on the cap and “1381” on the body and are supplied in: Bottles of 100 (NDC 0527-1381-01). Bottles of 200 (NDC 0527-1381-04). Clindamycin HCl capsules, USP (equivalent to 150 mg of clindamycin) are available as light blue opaque and light green capsules imprinted with logo “LANNETT” on the cap and “1382” on the body and are supplied in: Bottles of 100 (NDC 0527-1382-01). Clindamycin HCl capsules, USP (equivalent to 300 mg of clindamycin) are available as light blue opaque capsules imprinted with logo “LANNETT” on the cap and “1383” on the body and are supplied in: Bottles of 16 (NDC 0527-1383-02). Bottles of 100 (NDC 0527-1383-01). Dispense in a tight container with a child-resistant closure.Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Efavirenz is an antiviral drug

Non-Clinical Toxicology
•tablets are contraindicated in patients with previously demonstrated clinically significant hypersensitivity (eg, Stevens-Johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of  components of this product. • of efavirenz with elbasvir and grazoprevir is contraindicated

Nifedipine is mainly eliminated by metabolism and is a substrate of CYP3A. Inhibitors and inducers of CYP3A can impact the exposure to nifedipine and consequently its desirable and undesirable effects. and data indicate that nifedipine can inhibit the metabolism of drugs that are substrates of CYP3A, thereby increasing the exposure to other drugs. Nifedipine is a vasodilator, and co-administration of other drugs affecting blood pressure may result in pharmacodynamic interactions.

Efavirenz plasma concentrations may be altered by substrates, inhibitors, or inducers of CYP3A. Likewise, efavirenz may alter plasma concentrations of drugs metabolized by CYP3A or CYP2B6. The most prominent effect of efavirenz at steady-state is induction of CYP3A and CYP2B6

The most significant adverse reactions observed in patients treated with efavirenz tablets are: • psychiatric symptoms • nervous system symptoms • rash • hepatotoxicity

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).